Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases
Overview
Oncology
Authors
Affiliations
Advances in gene therapy technologies, particularly in gene editing, are suggesting new avenues for the treatment of human immunodeficiency virus and other infectious diseases. This article outlines recent developments in antiviral gene therapies, including those based on the disruption of entry receptors or that target viral genomes using targeted nucleases, such as the CRISPR/Cas9 system. In addition, new ways to express circulating antiviral factors, such as antibodies, and approaches to harness and engineer the immune system to provide an antiviral effect that is not naturally achieved are described.
Cornetta K, Bonamino M, Mahlangu J, Mingozzi F, Rangarajan S, Rao J Mol Ther. 2022; 30(6):2122-2129.
PMID: 35390542 PMC: 9171243. DOI: 10.1016/j.ymthe.2022.04.002.
Schwarzer R, Gramatica A, Greene W Viruses. 2020; 12(2).
PMID: 32046251 PMC: 7077203. DOI: 10.3390/v12020188.
Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G.
Delviks-Frankenberry K, Ackerman D, Timberlake N, Hamscher M, Nikolaitchik O, Hu W Mol Ther Nucleic Acids. 2019; 18:1023-1038.
PMID: 31778955 PMC: 6889484. DOI: 10.1016/j.omtn.2019.10.024.
Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection.
Lampi Y, Van Looveren D, Vranckx L, Thiry I, Bornschein S, Debyser Z Sci Rep. 2019; 9(1):2389.
PMID: 30787394 PMC: 6382798. DOI: 10.1038/s41598-019-38718-0.
Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.
Frank A, Buchholz C Mol Ther Methods Clin Dev. 2018; 12:19-31.
PMID: 30417026 PMC: 6216101. DOI: 10.1016/j.omtm.2018.10.006.